REVIEW article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1551415
Current Research Status on HER2 Protein Expression Levels and the Efficacy of Targeted Therapy in Breast Cancer
Provisionally accepted
- 1Baoding No.1 Central Hospital, Baoding, China
- 2Affiliated Hospital of Hebei University, Baoding, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This review summarizes the relationship between HER2 protein expression and the efficacy of three anti-HER2 targeted therapies in breast cancer patients: monoclonal antibodies, antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). The effectiveness of monoclonal antibody therapies positively correlates with HER2 protein expression levels, with HER2 IHC 3+ patients exhibiting better outcomes than IHC 2+/FISH+ patients. In contrast, those with low HER2 protein expression (IHC 1+ or 2+/FISH–) were not beneficial. In patients with HER2-positive breast cancer, the efficacy of T-DM1 is independent of HER2 protein expression levels. Patients with different HER2 expression levels can benefit from T-DXd treatment, with a potential positive correlation with HER2 expression levels. For TKIs, efficacy appeared to be positively correlated with HER2 expression, with HER2 IHC 3+ patients outperforming those with HER2 IHC 1+ or 2+/ISH+. However, high-level evidence to evaluate the relationship between HER2 expression levels and the efficacy of different targeted therapies is lacking. Determining whether HER2 protein expression levels influence treatment outcomes and whether tailored strategies based on HER2 protein expression levels should be implemented holds significant implications for advancing precision medicine in breast cancer.
Keywords: HER2 protein expression, breast cancer, targeted therapy, efficacy prediction, treatment strategies
Received: 25 Dec 2024; Accepted: 18 Jun 2025.
Copyright: © 2025 Liu, Peng, Yue, Huang, Du and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chongzhu Hu, Baoding No.1 Central Hospital, Baoding, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.